Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 17 12 2021
revised: 05 01 2022
accepted: 14 01 2022
pubmed: 30 1 2022
medline: 8 4 2022
entrez: 29 1 2022
Statut: ppublish

Résumé

Background Teriflunomide (TFL) is an oral drug used for treatment of multiple sclerosis (MS). Due to possible teratogenicity it is contraindicated in women of childbearing potential. Additionally, a low risk of male-mediated embryo-fetal toxicity has been described as the drug can be transmitted via semen. This study investigated the association of adverse perinatal outcomes in newborns with either maternal or paternal exposure to TFL. Methods The Danish Multiple Sclerosis Registry was used to identify all patients treated with teriflunomide from 1st of September 2013 to 31st of December 2018. Data were merged with other nationwide national registries to identify all pregnancies with potential exposure to TFL. Exposure was defined as conception occurring after at least 30 consecutive days of treatment either during treatment or within two years of treatment discontinuation. Exposed pregnancies were matched 1:4 with controls from the general population. Individual outcomes of adverse perinatal events, namely preterm birth, congenital malformations, small for gestational age (SGA), stillbirth or low Apgar score were used to form a composite outcome, any adverse event, which was used for the analysis. Logistic regression was used to estimate the association of having any adverse event in newborns with either maternal or paternal exposure to TFL. Results A total of 112 TFL-exposed pregnancies were included of which 49 had maternal exposure and 63 paternal exposure. Among women, 21/49 pregnancies were terminated - 18 electively and three spontaneously. The remaining 28 pregnancies resulted in healthy newborns of which ≤3 were preterm. None of the newborns presented with malformations, being SGA or with low Apgar score. Among men, all 63 pregnancies resulted in birth of which 4/63 (6.3%) were preterm. Major malformations were registered in ≤3 event, and no newborn presented with low Apgar score or being SGA. No increased association of any adverse event was found in newborns with TFL exposure relative to controls (OR 1.03, 95% CI 0.50-2.13). Conclusion We did not find an increased prevalence of spontaneous abortion, preterm birth, congenital malformations, low Apgar score of being SGA in newborns with maternal or paternal exposure to TFL when compared with the general population. However, the sample was too small to draw firm conclusions.

Identifiants

pubmed: 35091367
pii: S2211-0348(22)00044-X
doi: 10.1016/j.msard.2022.103529
pii:
doi:

Substances chimiques

Crotonates 0
Hydroxybutyrates 0
Nitriles 0
Toluidines 0
teriflunomide 1C058IKG3B

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103529

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Johanna Balslev Andersen (JB)

Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Valdemar Hansensvej 2, Rigshospitalet, Glostrup 2600, Denmark. Electronic address: johanna.balslev.andersen@regionh.dk.

Malthe Faurschou Wandall-Holm (MF)

Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Valdemar Hansensvej 2, Rigshospitalet, Glostrup 2600, Denmark.

Melinda Magyari (M)

Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Valdemar Hansensvej 2, Rigshospitalet, Glostrup 2600, Denmark; Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH